Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Alector, Inc. ALEC
$7.25
-$0.11 (-1.56%)
На 18:01, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
620137392.00000000
-
week52high
13.50
-
week52low
5.76
-
Revenue
133617000
-
P/E TTM
-5
-
Beta
0.78231900
-
EPS
-1.57000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 авг 2023 г. в 10:59
Описание компании
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Citigroup | Buy | Buy | 11 июл 2022 г. |
| Mizuho | Buy | 07 июл 2022 г. | |
| Goldman Sachs | Sell | Sell | 24 мая 2022 г. |
| Barclays | Overweight | Overweight | 11 мая 2022 г. |
| Goldman Sachs | Sell | 13 апр 2022 г. | |
| Morgan Stanley | Equal-Weight | Overweight | 09 сент 2022 г. |
| Citigroup | Buy | Buy | 10 ноя 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Polaris Venture Management Co. VI, L.L.C. | D | 0 | 98533 | 16 ноя 2022 г. |
| Polaris Venture Management Co. VI, L.L.C. | A | 98533 | 98533 | 16 ноя 2022 г. |
| Polaris Venture Management Co. VI, L.L.C. | D | 11853817 | 500000 | 16 ноя 2022 г. |
| MCGUIRE TERRANCE | A | 26266 | 13133 | 16 ноя 2022 г. |
| MCGUIRE TERRANCE | D | 0 | 98533 | 16 ноя 2022 г. |
| MCGUIRE TERRANCE | A | 98553 | 98533 | 16 ноя 2022 г. |
| MCGUIRE TERRANCE | A | 22317 | 6429 | 16 ноя 2022 г. |
| MCGUIRE TERRANCE | D | 11853817 | 500000 | 16 ноя 2022 г. |
| King Robert | A | 14384 | 14384 | 01 окт 2022 г. |
| King Robert | A | 550871 | 21576 | 01 окт 2022 г. |
Новостная лента
Does Alector (ALEC) Have the Potential to Rally 86.38% as Wall Street Analysts Expect?
Zacks Investment Research
09 мая 2023 г. в 11:28
The consensus price target hints at an 86.4% upside potential for Alector (ALEC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
04 мая 2023 г. в 21:17
Alector (ALEC) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $0.54 per share a year ago.
Alector: Trading At Cash Despite Late Stage CNS Pipeline
Seeking Alpha
03 февр 2023 г. в 14:13
Alector, Inc. has a lot of cash for a small biotech, but it is also trading at cash. Alector, Inc. has a late-stage program in a CNS indication and major big pharma deals.
Alector (ALEC) Reports Q3 Loss, Lags Revenue Estimates
Zacks Investment Research
08 ноя 2022 г. в 21:04
Alector (ALEC) delivered earnings and revenue surprises of -30.23% and 71.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential
Seeking Alpha
04 окт 2022 г. в 05:42
Initiation of phase 1 study of first clinical drug AL044 targeting MS4A for Alzheimer's Disease has been achieved. AbbVie for now remains committed with Alector in advancing AL002, which targets TREM2 for Alzheimer's Disease, in the ongoing INVOKE-2 phase 2 study.